Twilight Venture Partners

Twilight Venture Partners, LLC is a life-sciences venture capital firm founded in September 2002 and headquartered in Indianapolis, Indiana, investing exclusively in early-stage biotechnology and medical-technology companies. The firm is distinguished by an operator-led partnership: its team of around six partners are former executives from the pharmaceutical and medical-device industries, including founders of Guidant Corporation, who collectively bring more than 150 years of life-science experience and have worked together for over 25 years. Each partner has CEO-level experience, which they use both to select outstanding companies and to provide hands-on strategic guidance. Twilight backs companies developing precision peptide therapies, minimally invasive surgical devices and innovative diagnostics, primarily investing at the Series A stage in US-based startups while increasingly orienting its strategy toward opportunities in the Asian market, offering capital alongside a global network, generally as a co-investor. The firm is led by Managing Partner Aaron Pearson and Senior Managing Partner James M. Cornelius, and has raised multiple vehicles, Twilight Venture Partners I and II. Across roughly 21 investments it has produced one IPO and several acquisitions, with named portfolio companies including MBX Biosciences, Endocyte, BioStorage Technologies, NeoChord and NICO, whose exit came in September 2024. Specific fund sizes and cheque ranges are not publicly disclosed. By pairing deep operating experience from the pharmaceutical and medical-device industries with early-stage capital, Twilight Venture Partners backs founders developing therapeutics, surgical devices and diagnostics, increasingly bridging US innovation with Asian market opportunities.